ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OPTI Optibiotix Health Plc

19.60
-1.40 (-6.67%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.40 -6.67% 19.60 20.00 20.50 21.50 20.25 21.00 572,429 16:35:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 7.13 18.47M

OptiBiotix Health PLC Exercise of Warrants and Issue of Equity (6220Q)

01/12/2016 7:00am

UK Regulatory


Optibiotix Health (LSE:OPTI)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Optibiotix Health Charts.

TIDMOPTI

RNS Number : 6220Q

OptiBiotix Health PLC

01 December 2016

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Exercise of Warrants and Issue of Equity

OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that the Company has received notification from warrant holders to exercise warrants over 13,725 ordinary shares of 2p each in the Company at an exercise price of 8p per share, providing the Company with gross proceeds of GBP1,098.

Application will be made to the London Stock Exchange to admit the 13,725 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 6 December 2016. The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 78,164,259 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information:

 
 OptiBiotix Health plc                  www.optibiotix.com 
 Stephen O'Hara, Chief          Contact via Walbrook below 
  Executive 
 
 Cairn Financial Advisers               Tel: 020 7148 7900 
  LLP 
 Liam Murray / Tony Rawlinson 
 
 Hybridan LLP (Joint Broker) 
  Claire Louise Noyce                   Tel: 020 3764 2341 
 Peterhouse Corporate Finance           Tel: 020 7469 0936 
  Ltd (Joint Broker) 
 Lucy Williams / Duncan 
  Vasey 
 
 Walbrook PR Ltd                     Tel: 020 7933 8780 or 
                                 optibiotix@walbrookpr.com 
 Anna Dunphy                            Mob: 07876 741 001 
 Mike Wort                              Mob: 07900 608 002 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCDMMFMNGLGVZM

(END) Dow Jones Newswires

December 01, 2016 02:00 ET (07:00 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart

Your Recent History

Delayed Upgrade Clock